Homework Help is Here – Start Your Trial Now!
Science
Nursing
nursing care plan

nursing care plan

Phlebotomy Essentials
Phlebotomy Essentials
6th Edition
ISBN:9781451194524
Author:Ruth McCall, Cathee M. Tankersley MT(ASCP)
Publisher:Ruth McCall, Cathee M. Tankersley MT(ASCP)
Chapter1: Phlebotomy: Past And Present And The Healthcare Setting
Section: Chapter Questions
Problem 1SRQ
See similar textbooks
icon
Related questions
Question
nursing care plan
9:05 ull ? Done CASE SCENARIO ON ELDERLY PATIENT WITH IMPAIRED RENAL FUNCTION An 84-year-old man with type 2 diabetes is admitted to the hospital with altered mental status and hypoglycemia. He had experienced recurring episodes of mild hypoglycemia over the previous week, which were managed with food. With this episode, however, he could not be aroused, so the family called EMS. His past medical history includes chronic lymphocytic leukemia, gout, hypertension, and atrial fibrillation. Approximately 6 weeks ago, his serum creatinine increased from 1.6 mg/dL to 2.4 mg/dL following a bout of pneumonia. He had been taking glimepiride 4 mg twice daily. He admitted that he sometimes skipped the dose entirely because of hypoglycemia, and when he did so, his glucose was >200 mg/dL. His glycosylated hemoglobin (HbA1c) is 6.9%. Information and laboratory values collected at the hospital are as follows: •Height, 5'9" •Weight, 198 Ib •BMI, 28 •BP, 114/73 mm Hg •Current medications, glimepiride 4 mg BID and atorvastatin 10 mg QD •HBA1C, 6.9% • Lipids, LDL-C 45 mg/dL; HDL-C 55 mg/dL; Total-C 109 mg/dL; triglycerides 47 mg/dL •Serum creatinine 1.94 mg/dL DIAGNOSIS The patient is found to have acceptable glycemic control, but unacceptable episodes of severe hypoglycemia. His worsening renal dysfunction and poor overall health status were likely responsible for the hypoglycemia, since he had tolerated glimepiride in the past. Hypoglycemia with his current treatment regimen was a particular concern given his age, concomitant renal disease, and other comorbidities. TREATMENT While in the hospital, the patient required a small dose of Insulin Glargine to control his blood glucose, 16 units. This patient is elderly and has other comorbidities, including moderate renal impairment. Developing a treatment plan that helps maintain normal glucose levels with little or no associated hypoglycemia as well as limited complexity is important for this elderly patient.1 Since this patient has moderate renal impairment, it is important to consider medications that are not cleared renally and do not require dose adjustment based on serum creatinine or kidney function. Lastly, renal dysfunction and advanced age are two key risk factors for hypoglycemia.1- At discharge, the decision was made to discontinue insulin glargine and initiate oral therapy with a dipeptidyl peptidase-4 inhibitor, given the low rates of hypoglycemia associated with this class and ease of use (ie, oral administration). Linagliptin 5 mg/day was prescribed at hospital discharge, and a follow-up visit was scheduled in 2 weeks. At the follow-up appointment, the patient reported that he was feeling well and eating better. He stated that his glucose ranged from 140 mg/dL to 210 mg/dL. His serum creatinine had increased to 2.4 mg/dL. He has had no hypoglycemic episodes since leaving the hospital. At this time, a small dose of insulin gla wering regiment (8
Transcribed Image Text:9:05 ull ? Done CASE SCENARIO ON ELDERLY PATIENT WITH IMPAIRED RENAL FUNCTION An 84-year-old man with type 2 diabetes is admitted to the hospital with altered mental status and hypoglycemia. He had experienced recurring episodes of mild hypoglycemia over the previous week, which were managed with food. With this episode, however, he could not be aroused, so the family called EMS. His past medical history includes chronic lymphocytic leukemia, gout, hypertension, and atrial fibrillation. Approximately 6 weeks ago, his serum creatinine increased from 1.6 mg/dL to 2.4 mg/dL following a bout of pneumonia. He had been taking glimepiride 4 mg twice daily. He admitted that he sometimes skipped the dose entirely because of hypoglycemia, and when he did so, his glucose was >200 mg/dL. His glycosylated hemoglobin (HbA1c) is 6.9%. Information and laboratory values collected at the hospital are as follows: •Height, 5'9" •Weight, 198 Ib •BMI, 28 •BP, 114/73 mm Hg •Current medications, glimepiride 4 mg BID and atorvastatin 10 mg QD •HBA1C, 6.9% • Lipids, LDL-C 45 mg/dL; HDL-C 55 mg/dL; Total-C 109 mg/dL; triglycerides 47 mg/dL •Serum creatinine 1.94 mg/dL DIAGNOSIS The patient is found to have acceptable glycemic control, but unacceptable episodes of severe hypoglycemia. His worsening renal dysfunction and poor overall health status were likely responsible for the hypoglycemia, since he had tolerated glimepiride in the past. Hypoglycemia with his current treatment regimen was a particular concern given his age, concomitant renal disease, and other comorbidities. TREATMENT While in the hospital, the patient required a small dose of Insulin Glargine to control his blood glucose, 16 units. This patient is elderly and has other comorbidities, including moderate renal impairment. Developing a treatment plan that helps maintain normal glucose levels with little or no associated hypoglycemia as well as limited complexity is important for this elderly patient.1 Since this patient has moderate renal impairment, it is important to consider medications that are not cleared renally and do not require dose adjustment based on serum creatinine or kidney function. Lastly, renal dysfunction and advanced age are two key risk factors for hypoglycemia.1- At discharge, the decision was made to discontinue insulin glargine and initiate oral therapy with a dipeptidyl peptidase-4 inhibitor, given the low rates of hypoglycemia associated with this class and ease of use (ie, oral administration). Linagliptin 5 mg/day was prescribed at hospital discharge, and a follow-up visit was scheduled in 2 weeks. At the follow-up appointment, the patient reported that he was feeling well and eating better. He stated that his glucose ranged from 140 mg/dL to 210 mg/dL. His serum creatinine had increased to 2.4 mg/dL. He has had no hypoglycemic episodes since leaving the hospital. At this time, a small dose of insulin gla wering regiment (8
9:05 ull ? •Lipids, LDL-C 45 mg/dL; HDL-C 55 mg/dL; Total-C 109 mg/dL; triglycerides 47 mg/dL •Serum creatinine 1.94 mg/dL DIAGNOSIS The patient is found to have acceptable glycemic control, but unacceptable episodes of severe hypoglycemia. His worsening renal dysfunction and poor overall health status were likely responsible for the hypoglycemia, since he had tolerated glimepiride in the past. Hypoglycemia with his current treatment regimen was a particular concern given his age, concomitant renal disease, and other comorbidities. TREATMENT While in the hospital, the patient required a small dose of Insulin Glargine to control his blood glucose, 16 units. This patient is elderly and has other comorbidities, including moderate renal impairment. Developing a treatment plan that helps maintain normal glucose levels with little or no associated hypoglycemia as well as limited complexity is important for this elderly patient.1 Since this patient has moderate renal impairment, it is important to consider medications that are not cleared renally and do not require dose adjustment based on serum creatinine or kidney function. Lastly, renal dysfunction and advanced age are two key risk factors for hypoglycemia.1- At discharge, the decision was made to discontinue insulin glargine and initiate oral therapy with a dipeptidyl peptidase-4 inhibitor, given the low rates of hypoglycemia associated with this class and ease of use (ie, oral administration). Linagliptin 5 mg/day was prescribed at hospital discharge, and a follow-up visit was scheduled in 2 weeks. At the follow-up appointment, the patient reported that he was feeling well and eating better. He stated that his glucose ranged from 140 mg/dL to 210 mg/dL. His serum creatinine had increased to 2.4 mg/dL. He has had no hypoglycemic episodes since leaving the hospital. At this time, a small dose of insulin glargine was added to his glucose-lowering regiment (8 units), with adjustments made on an outpatient basis. At a 6-month follow-up, the patient's HbA1c was 6.6%. He reported that his glucose ranges from 110 mg/dL to 155 mg/dL, and he had not experienced any hypoglycemia. His serum creatinine was 1.99 mg/dL. Information and laboratory values collected during the 6- month follow-up visit are summarized here: •Weight, 186 Ib •BP, 112/70 mm Hg •Current medications, Linagliptin 5 mg/d; Insulin Glargine 10-14 units/day; Atorvastatin 10 mg QD •HBA1C, 6.6% •Lipids, LDL-C 28 mg/dL; HDL-C 38 mg/dL; Total-C 103 mg/dL; triglycerides 73 mg/dL •Serum creatinine 1.99 mg/dL Over the next 2 years, the patient's serum creatinine fluctuated from 1.7 mg/dL to 2.5 mg/dL. He required additional chemotherapy for chronic lymphocytic leukemia with small cell lymphoma. His diabetes remained stable on the same regimen of linagliptin 5 mg/day and insulin glargine 10 to 14 units/day.
Transcribed Image Text:9:05 ull ? •Lipids, LDL-C 45 mg/dL; HDL-C 55 mg/dL; Total-C 109 mg/dL; triglycerides 47 mg/dL •Serum creatinine 1.94 mg/dL DIAGNOSIS The patient is found to have acceptable glycemic control, but unacceptable episodes of severe hypoglycemia. His worsening renal dysfunction and poor overall health status were likely responsible for the hypoglycemia, since he had tolerated glimepiride in the past. Hypoglycemia with his current treatment regimen was a particular concern given his age, concomitant renal disease, and other comorbidities. TREATMENT While in the hospital, the patient required a small dose of Insulin Glargine to control his blood glucose, 16 units. This patient is elderly and has other comorbidities, including moderate renal impairment. Developing a treatment plan that helps maintain normal glucose levels with little or no associated hypoglycemia as well as limited complexity is important for this elderly patient.1 Since this patient has moderate renal impairment, it is important to consider medications that are not cleared renally and do not require dose adjustment based on serum creatinine or kidney function. Lastly, renal dysfunction and advanced age are two key risk factors for hypoglycemia.1- At discharge, the decision was made to discontinue insulin glargine and initiate oral therapy with a dipeptidyl peptidase-4 inhibitor, given the low rates of hypoglycemia associated with this class and ease of use (ie, oral administration). Linagliptin 5 mg/day was prescribed at hospital discharge, and a follow-up visit was scheduled in 2 weeks. At the follow-up appointment, the patient reported that he was feeling well and eating better. He stated that his glucose ranged from 140 mg/dL to 210 mg/dL. His serum creatinine had increased to 2.4 mg/dL. He has had no hypoglycemic episodes since leaving the hospital. At this time, a small dose of insulin glargine was added to his glucose-lowering regiment (8 units), with adjustments made on an outpatient basis. At a 6-month follow-up, the patient's HbA1c was 6.6%. He reported that his glucose ranges from 110 mg/dL to 155 mg/dL, and he had not experienced any hypoglycemia. His serum creatinine was 1.99 mg/dL. Information and laboratory values collected during the 6- month follow-up visit are summarized here: •Weight, 186 Ib •BP, 112/70 mm Hg •Current medications, Linagliptin 5 mg/d; Insulin Glargine 10-14 units/day; Atorvastatin 10 mg QD •HBA1C, 6.6% •Lipids, LDL-C 28 mg/dL; HDL-C 38 mg/dL; Total-C 103 mg/dL; triglycerides 73 mg/dL •Serum creatinine 1.99 mg/dL Over the next 2 years, the patient's serum creatinine fluctuated from 1.7 mg/dL to 2.5 mg/dL. He required additional chemotherapy for chronic lymphocytic leukemia with small cell lymphoma. His diabetes remained stable on the same regimen of linagliptin 5 mg/day and insulin glargine 10 to 14 units/day.
Expert Solution
trending now

Trending now

This is a popular solution!

steps

Step by step

Solved in 3 steps

SEE SOLUTIONCheck out a sample Q&A here
Blurred answer
Recommended textbooks for you
Phlebotomy Essentials
Phlebotomy Essentials
Nursing
ISBN:
9781451194524
Author:
Ruth McCall, Cathee M. Tankersley MT(ASCP)
Publisher:
JONES+BARTLETT PUBLISHERS, INC.
Gould's Pathophysiology for the Health Profession…
Gould's Pathophysiology for the Health Profession…
Nursing
ISBN:
9780323414425
Author:
Robert J Hubert BS
Publisher:
Saunders
Fundamentals Of Nursing
Fundamentals Of Nursing
Nursing
ISBN:
9781496362179
Author:
Taylor, Carol (carol R.), LYNN, Pamela (pamela Barbara), Bartlett, Jennifer L.
Publisher:
Wolters Kluwer,
Fundamentals of Nursing, 9e
Fundamentals of Nursing, 9e
Nursing
ISBN:
9780323327404
Author:
Patricia A. Potter RN MSN PhD FAAN, Anne Griffin Perry RN EdD FAAN, Patricia Stockert RN BSN MS PhD, Amy Hall RN BSN MS PhD CNE
Publisher:
Elsevier Science
Study Guide for Gould's Pathophysiology for the H…
Study Guide for Gould's Pathophysiology for the H…
Nursing
ISBN:
9780323414142
Author:
Hubert BS, Robert J; VanMeter PhD, Karin C.
Publisher:
Saunders
Issues and Ethics in the Helping Professions (Min…
Issues and Ethics in the Helping Professions (Min…
Nursing
ISBN:
9781337406291
Author:
Gerald Corey, Marianne Schneider Corey, Cindy Corey
Publisher:
Cengage Learning
SEE MORE TEXTBOOKS